| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 103.05B | 100.97B | 101.36B | 97.40B | 81.60B | 63.57B |
| Gross Profit | 14.70B | 14.37B | 14.11B | 13.81B | 12.15B | 9.77B |
| EBITDA | 4.42B | 5.20B | 4.80B | 4.98B | 3.69B | 2.54B |
| Net Income | 2.42B | 2.66B | 2.50B | 2.74B | 2.09B | 1.34B |
Balance Sheet | ||||||
| Total Assets | 60.61B | 63.69B | 65.13B | 64.08B | 59.15B | 49.32B |
| Cash, Cash Equivalents and Short-Term Investments | 9.46B | 8.97B | 8.23B | 6.49B | 6.05B | 8.79B |
| Total Debt | 1.33B | 1.50B | 1.73B | 5.09B | 2.87B | 1.70B |
| Total Liabilities | 19.78B | 22.84B | 26.05B | 28.47B | 25.98B | 19.39B |
| Stockholders Equity | 40.81B | 40.82B | 39.06B | 35.59B | 33.16B | 29.93B |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | 1.72B | 5.97B | -916.00M | -1.25B | 2.77B |
| Operating Cash Flow | 0.00 | 1.82B | 6.08B | -716.00M | -890.00M | 3.14B |
| Investing Cash Flow | 0.00 | -95.00M | -84.00M | -191.00M | -3.81B | -981.00M |
| Financing Cash Flow | 0.00 | -1.31B | -4.42B | 1.20B | 2.05B | -660.00M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| ― | ¥55.54B | 15.52 | ― | 1.37% | 32.53% | 182.70% | |
| ― | ¥53.49B | 17.93 | ― | 1.87% | -0.46% | -25.32% | |
| ― | ¥25.48B | 6.55 | ― | 2.88% | -1.98% | 23.24% | |
| ― | ¥32.62B | 13.54 | ― | 3.13% | 2.04% | -11.59% | |
| ― | ¥27.06B | 9.40 | ― | 4.48% | 3.32% | 31.11% | |
| ― | $37.18B | 12.37 | -10.20% | 1.83% | 8.50% | -7.62% |
Takebishi Corporation has revised its earnings forecasts for the second quarter and full fiscal year ending March 2026, citing strong sales in its medical business and semiconductors and devices segment. The company anticipates exceeding previous profit forecasts due to efficient management of SG&A expenses, despite economic uncertainties and prolonged inventory adjustments.
The most recent analyst rating on (JP:7510) stock is a Hold with a Yen2101.00 price target. To see the full list of analyst forecasts on Takebishi Corporation stock, see the JP:7510 Stock Forecast page.
Takebishi Corporation has revised its earnings and dividend forecasts for the second quarter of the fiscal year ending March 31, 2026, citing strong performance in its medical business and increased demand in its ODM business. The company anticipates a slight increase in net sales and profits, and has raised its dividend per share by 2 yen, reflecting its commitment to returning profits to shareholders.
The most recent analyst rating on (JP:7510) stock is a Buy with a Yen2068.00 price target. To see the full list of analyst forecasts on Takebishi Corporation stock, see the JP:7510 Stock Forecast page.
Takebishi Corporation reported its consolidated financial results for the three months ended June 30, 2025, showing an increase in net sales by 8.9% year-on-year to ¥25,542 million. Despite the rise in sales and operating profit, the profit attributable to owners of the parent decreased by 23.7%, indicating potential challenges in cost management or other operational areas.